Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20509998 | 1.00 | PPARG (0.44) | PPARGPPARDPPARAHCRTR2HCRTR1 | |
| SCHEMBL22504373 | 0.85 | ESR2 (0.50) | PPARGPPARDPPARAHCRTR2HCRTR1 | |
| SCHEMBL31281239 | 0.85 | ESR2 (0.50) | PPARGPPARDPPARAHCRTR2HCRTR1 | |
| SCHEMBL29124178 | 0.85 | ESR2 (0.50) | PPARGPPARDPPARAHCRTR2HCRTR1 | |
| SCHEMBL22504368 | 0.81 | PPARG (0.45) | PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL31281225 | 0.80 | PPARG (0.44) | PPARGPPARDPPARA | |
| SCHEMBL19423659 | 0.76 | PNMT (0.42) | PPARGPPARDPPARA | |
| SCHEMBL22504328 | 0.76 | PLAU (0.44) | PPARGPPARDPPARA | |
| SCHEMBL18584721 | 0.75 | NAMPT (0.42) | NPC1KMT2AHSD17B10HDAC6 | |
| SCHEMBL16015559 | 0.74 | ALDH1A1 (0.45) | PPARGPPARDPPARAKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220483-B2 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators | CALDAN THERAPEUTICS LTD (GB) | 2022-01-11 | — | — | US | disclosed |
| US-20200317619-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LTD. (GB) | 2020-10-08 | — | — | US | disclosed |
| EP-3601229-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | Caldan Therapeutics Limited (GB) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172727-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LIMITED (GB) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317619-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | GPR119, GPR84, GPR65 | PPARG 62/4885PPARD 57/4885PPARA 233/4885 |
| US-11220483-B2 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators | GPR119, GPR84, GPR65 | PPARG 63/4885PPARD 56/4885PPARA 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.